AbbVie Inc. logo

AbbVie Inc. (4AB)

Market Closed
13 Jun, 15:30
XETRA XETRA
167. 00
+0.8
+0.48%
- Market Cap
42.2 P/E Ratio
6.2% Div Yield
325 Volume
10.28 Eps
166.2
Previous Close
Day Range
164.6 167
Year Range
147.6 204.45
Earnings results expected in 38 days

Summary

4AB closed Friday higher at €167, an increase of 0.48% from Thursday's close, completing a monthly decrease of -2.57% or €4.4. Over the past 12 months, 4AB stock lost -3.21%.
4AB pays dividends to its shareholders, with the most recent payment made on May 15, 2025. The next estimated payment will be in In 2 months on Aug 15, 2025 for a total of €1.64.
The last earnings report, released on Apr 24, 2025, exceeded the consensus estimates by 0%. On average, the company has surpassed earnings expectations by 0.26%, based on the last three reports. The next scheduled earnings report is due on Jul 23, 2025.
The stock of the company had never split.
The company's stock is traded on 15 different exchanges and in various currencies, with the primary listing on NYSE (USD).
Want to track 4AB and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!

4AB Chart

Chart

Empty chart
The chart has 2 Y axes displaying values, and values.
Loading, please wait...
End of interactive chart.
AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth

AbbVie: A Biotech Powerhouse Generating Explosive EPS And Dividend Growth

AbbVie is undervalued, trading at under 16x 2025 earnings, despite robust EPS growth, a strong pipeline, and successful Humira diversification. Skyrizi and Rinvoq are driving immunology revenue, expected to surpass $15 billion by 2027, with neuroscience and oncology portfolios also showing strong growth. AbbVie has delivered 11 consecutive years of dividend increases, with a 7.23% five-year CAGR and a current yield of 3.43%, rewarding shareholders consistently.

Seekingalpha | 5 hours ago
AbbVie's Post-Humira Strategy Is Paying Off For Investors

AbbVie's Post-Humira Strategy Is Paying Off For Investors

AbbVie offers a compelling blend of high yield, consistent dividend growth, and strong financials, making it attractive for income-focused investors. The company has successfully transitioned from Humira, with Rinvoq and Skyrizi driving impressive revenue growth and offsetting patent expirations. AbbVie's robust pipeline and strategic acquisitions position it for continued growth, supporting ongoing dividend increases and shareholder returns.

Seekingalpha | 6 hours ago
Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight

Giant-Cell Arteritis Market Heats up with AbbVie's RINVOQ Approval | DelveInsight

The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market. The FDA has approved AbbVie's RINVOQ (upadacitinib) for the treatment of giant cell arteritis, making it the ninth approved indication for the drug. This also marks the first time an oral JAK inhibitor has been approved for this prevalent form of vasculitis in Western countries. RINVOQ's approval has sparked competition among other pharmaceutical companies in the giant cell arteritis market.

Globenewswire | 3 days ago

AbbVie Inc. Dividends

AbbVie Inc. logo
4AB 8 months ago
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 11 months ago
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 12 Apr 2024
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 12 Jan 2024
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 12 Oct 2023
Other
€1.48 Per Share

AbbVie Inc. Earnings

23 Jul 2025 (38 Days) Date
-
Cons. EPS
-
EPS
24 Apr 2025 Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
0.8
EPS
25 Oct 2024 Date
-
Cons. EPS
-
EPS
AbbVie Inc. logo
4AB 8 months ago
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 11 months ago
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 12 Apr 2024
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 12 Jan 2024
Other
€1.55 Per Share
AbbVie Inc. logo
4AB 12 Oct 2023
Other
€1.48 Per Share
23 Jul 2025 (38 Days) Date
-
Cons. EPS
-
EPS
24 Apr 2025 Date
-
Cons. EPS
-
EPS
31 Jan 2025 Date
-
Cons. EPS
-
EPS
30 Oct 2024 Date
-
Cons. EPS
0.8
EPS
25 Oct 2024 Date
-
Cons. EPS
-
EPS

AbbVie Inc. (4AB) FAQ

What is the stock price today?

The current price is €167.00.

On which exchange is it traded?

AbbVie Inc. is listed on NYSE.

What is its stock symbol?

The ticker symbol is 4AB.

Does it pay dividends? What is the current yield?

It does not pay dividends to its shareholders.

What is its market cap?

As of today, no market cap data is available.

What is the earnings per share?

The EPS is 0.

When is the next earnings date?

The next earnings report will release on Jul 23, 2025.

Has AbbVie Inc. ever had a stock split?

No, there has never been a stock split.

AbbVie Inc. Profile

Drug Manufacturers - General Industry
Healthcare Sector
Mr. Robert A. Michael CPA CEO
XETRA Exchange
US00287Y1091 ISIN
US Country
55,000 Employees
15 Apr 2025 Last Dividend
- Last Split
2 Jan 2013 IPO Date

Overview

AbbVie Inc. is a global pharmaceutical company engaged in the discovery, development, manufacturing, and sales of a wide range of pharmaceutical products. Incorporated in 2012 and headquartered in North Chicago, Illinois, AbbVie focuses on addressing some of the world's most complex and critical health issues through its innovative medicines and therapies. In addition to its stand-alone operations, the company collaborates with several other leading institutions, including Calico Life Sciences LLC, REGENXBIO Inc., Janssen Biotech, Inc., Genentech, Inc., and Tentarix Biotherapeutics, LP. These collaborations aim to enhance AbbVie's research and development capabilities, particularly in the areas of oncology and immunology.

Products and Services

  • Humira: A therapeutic injection for various autoimmune diseases, including intestinal Behçet's disease and pyoderma gangrenosum.
  • Skyrizi: Prescribed for patients with moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease, focusing on improving skin health.
  • Rinvoq: Targets multiple conditions such as rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, and several gastrointestinal diseases.
  • Imbruvica: An oral medication for adults with various blood cancers, marking significant advancements in oncology.
  • Epkinly and Elahere: Treatments tailored for different forms of lymphoma and cancer, showcasing AbbVie's innovations in targeted therapies.
  • Venclexta/Venclyxto: Offers hope for patients battling blood cancers, through a regimen that interferes with cancer cell survival.
  • Aesthetic Products: A range of facial injectables, plastics and regenerative medicine, body contouring, and skincare offerings that cater to aesthetic needs.
  • Botox Therapeutic: Beyond cosmetic applications, this product is utilized for various therapeutic purposes, enhancing patient care.
  • Vraylar: A medication designed to address depressive disorder, contributing to mental health treatment options.
  • Duopa and Duodopa: These formulations provide relief for patients with advanced Parkinson's disease, improving quality of life.
  • Ubrelvy and Qulipta: Target the acute treatment of migraine in adults, including both episodic and chronic forms.
  • Ozurdex: An ocular implant designed to treat eye diseases, emphasizing AbbVie's contribution to ophthalmology.
  • Lumigan/Ganfort and Alphagan/Combigan: Aimed at reducing intraocular pressure in conditions like open-angle glaucoma or ocular hypertension.
  • Restasis: Helps increase tear production, addressing the needs of patients with dry eye disease.
  • Mavyret/Maviret: Administered for the treatment of chronic hepatitis C virus (HCV) infection, representing a breakthrough in HCV treatment.
  • Creon: A pancreatic enzyme therapy essential for patients with pancreatic insufficiency, aiding digestion.
  • Lupron: Utilized for treating advanced prostate cancer, endometriosis, central precocious puberty, and uterine fibroids-related anemia.
  • Linzess/Constella: Offers relief for irritable bowel syndrome with constipation and chronic idiopathic constipation.
  • Synthroid: A synthetic thyroid hormone used to treat hypothyroidism, ensuring thyroid hormone levels are balanced.

Contact Information

Address: 1 North Waukegan Road
Phone: 847 932 7900